Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers
DOI: https://doi.org/10.2147/dddt.s454774
IF: 4.3188
2024-06-05
Drug Design Development and Therapy
Abstract:Dan Lv, 1 Yuling Liu, 1 Ruying Tang, 1 Sai Fu, 1 Shasha Kong, 1 Qian Liao, 1 Hui Li, 1, 2 Longfei Lin 1 1 Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, People's Republic of China; 2 Institute of Traditional Chinese Medicine Health Industry, China Academy of Chinese Medical Sciences, Jiangxi, 330006, People's Republic of China Correspondence: Hui Li; Longfei Lin, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Nanxiaojie 16, 8 Dongzhimennei Ave, Beijing, 100700, People's Republic of China, Tel +86-10-64032658, Email ; The potential anti-cancer effect of traditional Chinese medicine (TCM) monomers has been widely studied due to their advantages of well-defined structure, clear therapeutic effects, and easy quality control during the manufacturing process. However, clinical trial information on these monomers is scarce, resulting in a lack of knowledge regarding the research progress, efficacy, and adverse reactions at the clinical stage. Therefore, this study systematically reviewed the clinical trials on the anti-cancer effect of TCM monomers registered in the Clinicaltrials.gov website before 2023.4.30, paying special attention to the trials on tumors, aiming to explore the research results and development prospects in this field. A total of 1982 trials were started using 69 of the 131 TCM monomers. The number of clinical trials performed each year showed an overall upward trend. However, only 26 monomers entered into 519 interventional anti-tumor trials, with vinblastine (194, 37.38%) and camptothecin (146, 28.13%) being the most used. A total of 45 tumors were studied in these 519 trials, with lymphoma (112, 21.58%) being the most frequently studied. Clinical trials are also unevenly distributed across locations and sponsors/collaborators. The location and the sponsor/collaborator with the highest number of performed trials were the United States (651,32.85%) and NIH (77). Therefore, China and its institutions still have large room for progress in promoting TCM monomers in anti-tumor clinical trials. In the next step, priority should be given to the improvement of the research and development ability of domestic enterprises, universities and other institutions, using modern scientific and technological means to solve the problems of poor water solubility and strong toxic and side effects of monomers, so as to promote the clinical research of TCM monomers. Keywords: traditional Chinese medicine monomers, anti-cancer, interventional clinical trials, research progress, adverse reactions To date, cancer remains a major public health challenge. At present, the incidence of six types of tumors, including adolescent colorectal cancer, continues to increase. 1,2 Moreover, cancer is probably becoming the leading cause of premature death in most countries in the 21st century. 3 Common treatments include surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. 4,5 However, these methods are more or less limited by the treatment conditions, the type/grade of tumor and the potential complications. In China, traditional Chinese medicine (TCM) has unique characteristics in treating cancer for thousands of years. Chinese medicinal monomers with well-defined structures have been isolated from Chinese herbs thanks to the help of modern scientific and technological means, showing superior anti-tumor effects. 6–12 Chinese medicinal monomers represent great research and development potential as new anti-tumor drugs due to the characteristics of clear structure, definite effects, and easy-to-control quality process. Previous studies provided detailed analyses of the drug development profile in China, 13 the characteristics of clinical trials of new TCMs, 14 and the clinical trials on specific tumors. 15,16 However, there are few reviews worldwide summarizing the characteristics of clinical trials that used anti-tumor herbal monomers. The clinicaltrials.gov website, which is one of the most influential platforms in the world, was released by the National Institutes of Health (NIH) in 2000 and includes more than 450,000 clinical studies from all 50 states and 221 countries. This clinical trial registration platform is one of the most influential platforms in the world, containing data of many anti-tumor clinical trials using active ingredients of TCMs worldwide, providing a support for their further analysis. Therefore, this study systematically reviewed the clinical trials using anti-tumor TCM monomers registered in the Clinicaltrials.gov website before April 30, 2023. Moreover, this review focused on anti-tumor trials and explored the research -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal